QT alterations in psychopharmacology: Proven candidates and suspects

Current Drug Safety

Volumn 5, Issue 1, 2010, Pages 97-104

  Alvarez, Paulino Antonio ^a   Pahissa, Jaime ^a  

^a CEMIC   (Argentina)

Author keywords

Antidepressants; Antipsychotics; Psychotropics; QTc prolongation.; Torsades de pointes

Indexed keywords

AMITRIPTYLINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DOXEPIN; DROPERIDOL; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; MAPROTILINE; OLANZAPINE; PAROXETINE; PIMOZIDE; PLACEBO; POTASSIUM CHANNEL HERG; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; THIORIDAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

ACTION POTENTIAL; ALCOHOL CONSUMPTION; ANOREXIA NERVOSA; ATRIOVENTRICULAR CONDUCTION; BIPOLAR DISORDER; BIPOLAR MANIA; BRADYCARDIA; BRUGADA SYNDROME; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONGENITAL DEAFNESS; CONGESTIVE HEART FAILURE; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG INTOXICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAPHY MONITORING; ELECTROLYTE DISTURBANCE; ELECTROPHYSIOLOGY; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; GILLES DE LA TOURETTE SYNDROME; HEART ARREST; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IC 50; ISCHEMIC HEART DISEASE; LITHIUM BLOOD LEVEL; LONG TERM CARE; LUNG EMBOLISM; MANIA; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PATCH CLAMP; PHARMACODYNAMICS; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; POTASSIUM CURRENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; QT PROLONGATION; RADIOASSAY; RETINOPATHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SINUS TACHYCARDIA; SUBSTANCE ABUSE; SUDDEN DEAFNESS; SYNCOPE; T WAVE; TACHYCARDIA; TORSADE DES POINTES; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

AGE FACTORS; AGED; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; LONG QT SYNDROME; MALE; PSYCHOTROPIC DRUGS; RISK FACTORS; SEX FACTORS; TORSADES DE POINTES;

EID: 77950291923     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610789869265     Document Type: Review

References (116)

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350(10): 1013-1022
2. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21(15): 1216-1231
3. Darpo B. Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace 2007; 9(4): 23-36.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349(9064): 1498-1504
5. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289(23): 3095-3105
6. Chapman DP, Perry GS, Strine TW. The vital link between chronic disease and depressive disorders. Prev Chronic Dis. Available from: URL: www.cdc.gov/pcd/issues/ 2005/jan/04-0066.htm [Last Accessed: April 28,2009].
7. Kawas CH, Brookmeyer R. Aging and the public health effects of dementia. N Engl J Med 2001; 344(15): 1160-1161
8. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009; 85(1): 86-88
9. Inouye SK. Delirium in older persons. N Engl J Med 2006; 354(11): 1157-1165
10. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999: 156(Suppl 5): 1-20.
11. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003; 24(12): 619-625
12. Vincent GM. The long-QT syndrome-bedside to bench to bedside.N Engl J Med 2003; 348(19): 1837-1838
13. Snyders DJ. Structure and function of cardiac potassium channels. Cardiovasc Res 1999; 42(2): 377-390
14. Sanguinetti MC, Jiang C, Curran ME, Keating M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell 1995; 81(2): 299-307.
15. Tie H, Walker BD, Valenzuela SM, Breit SN, Campbell TJ. The heart of psychotropic drug therapy. Lancet 2000; 355(9217): 125.
16. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002; 450(1): 37-41.
17. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58(1): 32-45
18. Jo SH, Youm JB, Lee CO, Earm, YE, Ho WK. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol 2000; 129(7): 1474-1480
19. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 1999; 128(2): 479-485
20. Duncan RS, McPate MJ, Ridley JM, et al. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol 2007; 74(3): 425-437
21. Zitron E, Kiesecker C, Scholz E, et al. Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn Schmiedebergs Arch Pharmacol 2004; 370(2): 146-156
22. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 2002; 300(2): 543-548
23. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355(9209): 1048-1052
24. van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009; 29(1): 9-15.
25. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104(18): 2158-2163
26. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 1996; 93(3): 519-524
27. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005; 26(19): 2007-2012
28. Peele R, Von Loetzen IS. Phenothiazine deaths: a critical review. Am J Psychiatry 1973; 130(3): 306-309
29. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004; 164(12): 1293-1297
30. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58(12): 1161-1167
31. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 1070.
32. Gill SS, Bronskill SE., Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146(11): 775-786
33. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005; 353(22): 2335-2341
34. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360(3): 225-235
35. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75(3): 234-241 (Pubitemid 38314873)
36. Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol 2009; 53(11): 950-958
37. FDA. Information for Healthcare Professionals Antipsychotics. Available from: URL: http://www. fda.gov/cder/drug/InfoSheets/HCP/antipsychotics- conventional.htm [Last accessed: May 5, 2009]
38. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176(5): 627-632
39. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11): 1774-1782
40. Davidorf FH. Thioridazine pigmentary retinopathy. Arch Ophthalmol 1973; 90(3): 251-255
41. Hagopian V, Stratton DB, Busiek RD. Five cases of pigmentary retinopathy associated with thioridazine administration. Am J Psychiatry 1966; 123(1): 97-100.
42. Wright N. Removal of thioridazine from primary care formulary will result in prescribing vacuum. BMJ 2001; 323(7314): 695.
43. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas S. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002; 180: 515-522
44. Ray WA, Meador KG. Antipsychotics and sudden death: is thioridazine the only bad actor? Br J Psychiatry 2002; 180: 483-484
45. Mehtonen OP, Aranko K, Malkonen L, Vapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991; 84(1): 58-64.
46. Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. Society of Critical Care Medicine. Crit Care Med 1995; 23(9): 1596-1600
47. Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, Kishon Y. Haloperidol-induced torsades de pointes. Chest 1990; 98(2): 482-484
48. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and lowdose oral haloperidol. Arch Intern Med 1997; 157(17): 2013-2015
49. Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth 2000; 47(3): 251-254
50. Zee-Cheng CS, Mueller CE, Seifert CF, Gibbs HR. Haloperidol and torsades de pointes. Ann Intern Med 1985; 102(3): 418.
51. Hunt N, Stern TA. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. Psychosomatics 1995; 36(6): 541-549
52. Hayashi S, Kii Y, Tabo M, et al. QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. J Pharmacol Sci 2005; 99(5): 423-437 (Pubitemid 44618144)
53. Rasty S, Amin NB, Sabbah HN, Mishima T, Borzak S, Tisdale JE. Influence of i.v. haloperidol on ventricular repolarization and monophasic action potential duration in anesthetized dogs. Chest 2004; 125(5): 1821-1829
54. FDA. Information for Healthcare Professionals Haloperidol. Available from: URL: http://www.fda.gov/CDER/DRUG/InfoSheets/HCP/haloperidol.htm [Last accessed May 5,2009].
55. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62(11): 1649-1671
56. Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD001715. DOI: 10.1002/14651858.CD001715.pub2.
57. Peuskens J, Moore N, Azorin JM, Toumi M, Cochran J. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol Drug Saf 2007; 16(7): 804-811
58. Klein-Schwartz W, Lofton AL, Benson BE, Spiller HA, Crouch BI. Prospective observational multi-poison center study of ziprasidone exposures. Clin Toxicol (Phila) 2007; 45(7): 782-786
59. Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005; 44(1): 73-79
60. Loebel A, Miceli J, Chappell P, Siu C. Electrocardiographic changes with ziprasidone. J Am Acad Child Adolesc Psychiatry 2006; 45(6): 636-637
61. Centorrino F, MacLean E, Salvatore P, et al. Ziprasidone: first year experience in a hospital setting. J Psychiatr Pract 2004; 10(6): 361-367
62. Levy WO, Robichaux-Keene NR, Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract 2004; 10(4): 227-232
63. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics 2006; 47(3): 264-268
64. Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol 2003; 41(2): 101-104
65. Stroup TS, Geddes JR. Randomized controlled trials forschizophrenia: study designs targeted to distinct goals. Schizophr Bull 2008; 34(2): 266-274
66. Kapur S, Zipursky RB, Remington G. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155(7): 921-928
67. Narasimhan M, Bruce TO, Masand P. Review of olanzapine in the management of bipolar disorders. Neuropsychiatr Dis Treat 2007; 3(5): 579-587
68. Morissette P, Hreiche R, Mallet L, Vo D, Knaus EE, Turgeon J. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol 2007; 21(7): 735-741
69. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24(1): 62-69
70. Gurovich I, Vempaty A, Lippmann S. QTc prolongation: chlorpromazine and high-dosage olanzapine. Can J Psychiatry 2003; 48(5): 348. (Pubitemid 36841275)
71. Su KP, Lane HY, Chuang CL, Chen KP, Shen WW. Olanzapineinduced QTc prolongation in a patient with Wolff-Parkinson-White syndrome. Schizophr Res 2004; 66(2-3): 191-192
72. Dineen S, Withrow K, Voronovitch L, Munshi F, Nawbary MW, Lippmann S. QTc prolongation and high-dose olanzapine. Psychosomatics 2003; 44(2): 174-175
73. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6): 825-835
74. Tan HH, Hoppe J, Heard K. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med 2009; 27(5): 607-616
75. Tanner MA, Culling W. Clozapine associated dilated cardiomyopathy. Postgrad Med J 2003: 79(933): 412-413
76. Lee SY, Kim YJ, Kim KT, Choe H, Jo SH. Blockade of HERG human K+ channels and Ikr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol 2006; 148(4): 499-509.
77. Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 2000; 20(3): 325-327
78. Rajamani S, Eckhardt LL, Valdivia CR, et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006; 149(5): 481-489
79. Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997; 17(1): 15-21.
80. Dubnov G, Fogelman R, Merlob P. Prolonged QT interval in an infant of a fluoxetine treated mother. Arch Dis Child 2005; 90(9): 972-973
81. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155(5): 660-665
82. Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999; 19(5): 407-415
83. Friberg LE, Isbister GK, Hackett LP, Duffull SB. The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn 2005; 32(3-4): 571-605.
84. Burckhardt D, Raeder E, Muller V, Imhof P, Neubauer H. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 1978; 239(3): 213-216
85. Glassman AH. Cardiovascular effects of tricyclic antidepressants. Annu Rev Med 1984; 35: 503-511
86. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004; 45(5): 371-377
87. Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002; 346(20):1591-1592
88. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325(7376): 1332-1333
89. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007; 64(2): 192-197
90. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (4): 1-50.
91. Hsu CH, Liu PY, Chen JH, Yeh TL, Tsai HY, Lin LJ. Electrocardiographic abnormalities as predictors for over-range lithium levels. Cardiology 2005; 103(2): 101-106
92. Mamiya K, Sadanaga T, Sekita A, Nabeyama Y, Yao H, Yukawa E. Lithium concentration correlates with QTc in patients with psychosis. J Electrocardiol 2005; 38(2): 148-151
93. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270(21): 2590-2597
94. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003; 82(4): 282-290
95. Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 2005; 111(3): 171-176
96. Lawrence DM, Holman CD, Jablensky AV, Hobbs MS. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry 2003; 182:31-36
97. Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349(10): 975-986
98. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med 2005; 352(6): 596-607.
99. Gamouras GA, Monir G, Plunkitt, K, Gursoy S, Dreifus LS. Cocaine abuse: repolarization abnormalities and ventricular arrhythmias. Am J Med Sci 2000; 320(1): 9-12.
100. Prosser JM, Mills A, Rhim ES, Perrone J. Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. Int J Emerg Med 2008; 1(3): 217-220
101. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137(6): 501-504
102. Zemrak WR, Kenna. GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 2008; 65(11): 1029-1038
103. Liu BA, Juurlink DN. Drugs and the QT interval - caveat doctor. N Engl J Med 2004; 351(11): 1053-1056
104. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354(5): 472-482
105. Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999; 14(1): 33-40.
106. De las Cuevas C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry 2004; 4: 18.
107. Viola R, Csukonyi K, Doro P, Janka Z, Soos G. Reasons for polypharmacy among psychiatric patients. Pharm World Sci 2004; 26(3): 143-147
108. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161(4): 700-706
109. Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005; 4(1): 1.
110. Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med 2008; 358(2): 169-176
111. Moric-Janiszewska E, Markiewicz-Loskot G, Loskot M, Weglarz L, Hollek A, Szydlowski L. Challenges of diagnosis of long-QT syndrome in children. Pacing Clin Electrophysiol 2007; 30(9): 1168-1170
112. Mehler PS. Clinical practice. Bulimia nervosa. N Engl J Med 2003; 349(9): 875-881
113. Kaplan EL. Oral erythromycin and the risk of sudden death. N Engl J Med 2005; 352(3): 301-304
114. Cooke RA, Chambers JB, Singh R, et al. QT interval in anorexia nervosa. Br Heart J 1994; 72(1): 69-73.
115. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349
116. Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999; 99: 979-982